Brucellosis Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Brucellosis Vaccines Market Report is Segmented by Vaccine Type (Live Attenuated, and More), Application (Cattle, Sheep & Goat, Other Applications), End User (Veterinary Hospitals & Clinics, Animal Care/Breeding Centres, Government & NGO Vaccination Campaigns), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Brucellosis Vaccines Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Brucellosis Vaccines Market with other markets in Healthcare Industry

Brucellosis Vaccines Market Analysis by Mordor Intelligence

The brucellosis vaccines market size stands at USD 273.31 million in 2025 and is forecast to reach USD 369.21 million by 2030, advancing at a 6.21% CAGR. Momentum comes from the growing recognition of brucellosis as a high-impact zoonosis that depresses livestock productivity and generates avoidable human illness costs. Policy-backed immunization programs, such as USDA’s Cooperative State-Federal effort and Canada’s province-level schemes, keep demand in developed economies resilient, while multilateral funds are widening access across lower-income regions. Intensifying livestock headcounts in South and Southeast Asia, rising consumer focus on milk and meat safety, and accelerated R&D in DNA and vector platforms collectively reinforce the long-run expansion of the brucellosis vaccines market. Strategic plant upgrades—illustrated by Merck Animal Health’s USD 895 million Kansas investment—are easing supply constraints and positioning leading producers to capture share when next-generation products clear regulators.

Key Report Takeaways

  • By vaccine type, live attenuated products led with 48.54% of brucellosis vaccines market share in 2024, whereas DNA vaccines are on track for the fastest 8.54% CAGR to 2030.
  • By application, cattle commanded 64.34% share of the brucellosis vaccines market size in 2024; the sheep and goat segment is projected to expand at 9.76% CAGR through 2030.
  • By end user, veterinary hospitals and clinics held 41.56% revenue share in 2024, while government and NGO campaigns record the highest 9.43% CAGR outlook.
  • By geography, North America accounted for 40.23% of the brucellosis vaccines market in 2024, whereas Asia-Pacific is advancing at a 7.65% CAGR through 2030.

Segment Analysis

By Vaccine Type: Innovation Fuels Gradual Shift from Live Attenuated Dominance

Live attenuated formulations such as RB51 and Rev-1 supplied 48.54% of brucellosis vaccines market share in 2024 thanks to field-proven 70–80% protection and lower cost of goods. These attributes will sustain baseline demand, particularly where eradication campaigns still rely on existing infrastructure. DNA candidates, however, are climbing at an 8.54% CAGR and are expected to carve measurable chunks of the brucellosis vaccines market by 2030 because they meet DIVA requirements and eliminate human infection fears associated with accidental self-inoculation. The EMA guidance released in 2025 removes much of the regulatory ambiguity that once deterred investment, encouraging firms with plasmid or multiepitope constructs to scale up pilot runs.

Sub-unit and recombinant protein lines continue serving niche users who prioritize biosafety, although their market expansion is tempered by adjuvant dependencies and cold-chain sensitivity. Vector-based platforms using bovine adenoviruses are advancing through late-stage pre-clinical milestones and could achieve field approval within the next planning cycle, especially for intranasal cattle dosing that sidesteps needle use and simplifies mass administration[3]Sayedahmed E. E. et al., “Bovine Adenoviral Vector Immunology,” frontiersin.org. Collectively, these technology streams ensure that the brucellosis vaccines market retains a diverse product mix that can respond to differing regulatory climates and herd management realities.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Small Ruminants Become the Standout Growth Frontier

Cattle immunization underpinned 64.34% of the brucellosis vaccines market size in 2024 on the back of decades-old eradication frameworks in North America and Europe and rising dairy herd upgrades in South Asia. Producers favor well-rehearsed schedules overseen by accredited veterinarians, and evidence from the United States shows roughly 3.5 million calves safeguarded annually with standardized tags and electronic record uploads. Yet small ruminant vaccination is accelerating at 9.76% CAGR, reflecting heightened concern over Brucella melitensis, which causes more severe human disease. Incentive contests such as the USD 30 million AgResults Brucellosis Vaccine Challenge channel funds toward safer Rev-1 replacements suitable for goat and sheep production in West Africa and Central Asi.

Economic modeling from Mexico’s small-scale goat systems confirms positive payback within five years, and similar analyses in North Africa suggest even faster returns where seroprevalence exceeds 8%. Wildlife vaccination remains a nascent field, but escalates in territories like the Greater Yellowstone Area, where elk and bison sustain sporadic spillover, reminding policymakers that full eradication demands cross-species vigilance.

Brucellosis Vaccines Market: Market Share by Application
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Public-Private Mechanics Diversify Delivery Channels

Veterinary hospitals and clinics held 41.56% of total revenue in 2024, reflecting their gatekeeper position for prescription-only biologics, cold-chain custody, and official tagging. Their role will stay central as live vaccines still dominate—and professional oversight is compulsory to mitigate accidental exposure. Meanwhile, government and NGO campaigns log a 9.43% CAGR, mobilized by evidence that comprehensive coverage cuts human incidence and raises rural incomes. Tajikistan’s 2023 outbreak response is illustrative: a coordinated taskforce delivered more than 5,000 doses within weeks, arresting spread and boosting producer trust.

Animal breeding centers, though a smaller slice of the brucellosis vaccines market, are evolving into advanced bio-security hubs; large dairy collectives in India and China now bundle routine Brucella immunization with genomic selection programs, thereby enhancing both herd health and genetic merit in a single intervention cycle. These dynamics underscore how differentiated end-user strategies will underpin revenue diversification across the brucellosis vaccines industry.

Geography Analysis

North America controlled 40.23% of the brucellosis vaccines market in 2024, an outcome linked to long-running eradication programs, mandatory RFID tagging, and generous federal cost-sharing arrangements. While domestic cattle incidence has been squeezed to isolated wildlife-related flare-ups in the Greater Yellowstone Area, the region’s proactive surveillance keeps annual prophylactic demand steady. The United States retains a deep ecosystem of biologic manufacturers, contract research organizations, and university extension networks that collectively sustain innovation and high coverage.

Asia-Pacific is the performance leader with a 7.65% CAGR outlook to 2030. India alone logs estimated brucellosis-linked economic losses of USD 3.4 billion per year, and recent cost-benefit assessments show vaccination can yield ratios above 20:1 for buffalo, prompting state governments to scale procurement. China’s concentration on protein security drives substantial investment in provincial Animal Husbandry Stations that bundle Brucella vaccination with TB and FMD programs, while Indonesia and Vietnam channel donor funds toward cold-chain reinforcement and farmer extension. The pace of herd expansion across ASEAN, particularly in small ruminants, guarantees a sizeable addition to the global brucellosis vaccines market.

Europe, backed by EMA’s stringent biologics code and harmonized disease notification laws, serves as a center of excellence for advanced platform trials, though endemic prevalence is already low in EU dairy herds. Middle East and Africa exhibit heterogeneous adoption; however, donor-driven pilots such as AgResults and IDRC’s Livestock Vaccine Innovation Fund are catalyzing uptake among smallholders in Kenya, Nigeria, and Ethiopia. South America’s picture ranges from sophisticated control in Uruguay’s beef sector to higher prevalence pockets in the Andean highlands, supporting a mixed demand trajectory yet preserving upside for manufacturers willing to tailor pack sizes and formulations.

Brucellosis Vaccines Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The brucellosis vaccines market shows moderate consolidation. Zoetis posted USD 9.3 billion total revenue in 2024, with livestock vaccines accounting for roughly one-third; its divestment of 37 medicated feed lines to Phibro refocuses capital on biologics R&D and manufacturing. Merck Animal Health’s USD 895 million Kansas facility expansion secures bulk antigen capacity and advanced fill-finish suites, helping buffer the sector against the Bangs vaccine shortage experienced in late 2024. Boehringer Ingelheim’s purchase of Saiba Animal Health adds virus-like particle technology that could spawn thermostable brucellosis candidates suitable for high ambient regions.

Second-tier players include Indian-based Indian Immunologicals and China’s Qingdao Vland, which concentrate on regional bulk supply contracts and increasingly co-license technology from multinationals to accelerate regulatory clearance. Collaborative ventures between Western IP holders and Asian manufacturers lower cost curves while spreading risk. At the same time, non-profit accelerators such as IDRC’s CAD 57 million Livestock Vaccine Innovation Fund are supplying grant capital to smaller biotech firms, offsetting the elevated proof-of-concept expenses associated with DIVA-enabled constructs.

Competitive advantages are shifting toward firms that combine versatile platform technologies with validated cold-chain service packages. Field data analytics—delivered via cloud dashboards and farm-level mobile apps—are gaining traction as differentiators, because they let manufacturers prove real-world efficacy and fine-tune batch planning. Regulatory agility also counts: companies with dedicated liaison units reduce dossier-to-license cycles by exploiting the mutual recognition channels now emerging among ASEAN members, Mercosur, and the Tripartite Alliance in Africa.

Brucellosis Vaccines Industry Leaders

  1. Ceva Santé Animale

  2. Zoetis Inc.

  3. Merck Animal Health

  4. Boehringer Ingelheim Animal Health

  5. Indian Immunologicals Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Global Brucellosis Vaccines Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: Elanco signed with Medgene to commercialize a highly pathogenic avian influenza vaccine for dairy cattle, pending USDA conditional approval.
  • January 2025: Merck Animal Health and Kansas announced a USD 895 million expansion of De Soto manufacturing and R&D facilities to boost veterinary vaccine output.
  • January 2025: The European Medicines Agency published comprehensive plasmid DNA vaccine guidelines, formalizing data requirements for veterinary use.
  • October 2024: Phibro closed a USD 350 million acquisition of Zoetis’ medicated feed additive portfolio, deepening its animal health footprint.
  • September 2024: Boehringer Ingelheim acquired Saiba Animal Health, adding virus-like particle know-how to its vaccine pipeline.

Table of Contents for Brucellosis Vaccines Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Brucellosis
    • 4.2.2 Government Supported Livestock Vaccination Programs
    • 4.2.3 Rising Awareness of Zoonotic Disease Risks
    • 4.2.4 Growth in Global Livestock Population
    • 4.2.5 Technological Advancements in Vaccine Platforms
    • 4.2.6 Availability of Funding And Incentive Initiatives
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory and DIVA Compliance Requirements
    • 4.3.2 Cold Chain and Distribution Constraints
    • 4.3.3 Safety Concerns Over Live Attenuated Vaccines
    • 4.3.4 Limited Veterinary Infrastructure in Emerging Regions
  • 4.4 Regulatory Landscape
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Vaccine Type
    • 5.1.1 Live Attenuated
    • 5.1.2 DNA Vaccine
    • 5.1.3 Sub-unit / Recombinant Protein
    • 5.1.4 Vector-Based / Viral-Vectored
  • 5.2 By Application
    • 5.2.1 Cattle
    • 5.2.2 Sheep & Goat
    • 5.2.3 Other Applications
  • 5.3 By End User
    • 5.3.1 Veterinary Hospitals & Clinics
    • 5.3.2 Animal Care / Breeding Centres
    • 5.3.3 Government & NGO Vaccination Campaigns
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Ceva Sant Animale
    • 6.3.2 Zoetis Inc.
    • 6.3.3 Merck Animal Health
    • 6.3.4 Boehringer Ingelheim Animal Health
    • 6.3.5 Indian Immunologicals Ltd
    • 6.3.6 Colorado Serum Company
    • 6.3.7 CZ Vaccines (Zendal)
    • 6.3.8 Jordan Bio-Industries Center (JOVAC)
    • 6.3.9 Laboratories Tornel
    • 6.3.10 Hester Biosciences
    • 6.3.11 Biogénesis Bagó
    • 6.3.12 Vaxxinova
    • 6.3.13 Elanco Animal Health
    • 6.3.14 Phibro Animal Health
    • 6.3.15 Chengdu Tecon Biologic
    • 6.3.16 China Animal Husbandry Group (CAHG)
    • 6.3.17 Shenyang Weiyuan Biopharmaceutical
    • 6.3.18 Anigen (Korea)

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Brucellosis Vaccines Market Report Scope

As per the scope, brucellosis is a bacterial disease caused by various Brucella species, mainly infecting cattle, swine, goats, sheep, and dogs. Humans acquire the disease through direct contact with infected animals, eating or drinking contaminated animal products, or inhaling airborne agents. The brucellosis vaccines market is segmented by vaccine type, application, end user, and geography. By vaccine type, the market is segmented into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By application, the market is segmented into cattle, sheep and goat, and other applications. By end user, the market is segmented into veterinary hospitals and clinics, animal care centers, and other end users. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).

By Vaccine Type Live Attenuated
DNA Vaccine
Sub-unit / Recombinant Protein
Vector-Based / Viral-Vectored
By Application Cattle
Sheep & Goat
Other Applications
By End User Veterinary Hospitals & Clinics
Animal Care / Breeding Centres
Government & NGO Vaccination Campaigns
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Vaccine Type
Live Attenuated
DNA Vaccine
Sub-unit / Recombinant Protein
Vector-Based / Viral-Vectored
By Application
Cattle
Sheep & Goat
Other Applications
By End User
Veterinary Hospitals & Clinics
Animal Care / Breeding Centres
Government & NGO Vaccination Campaigns
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the brucellosis vaccines market?

The brucellosis vaccines market size is USD 273.31 million in 2025 and is projected to grow to USD 369.21 million by 2030.

Which region is expanding the fastest?

Asia-Pacific is the fastest-growing region, registering a 7.65% CAGR through 2030 on the back of rising livestock numbers and greater disease-control funding.

Which vaccine type is gaining quickest adoption?

DNA vaccines post the highest 8.54% CAGR forecast because they meet DIVA standards and eliminate live-organism safety concerns.

How concentrated is the supplier landscape?

The market is moderately concentrated; the top five companies hold about 60% of sales, yielding a concentration score of 6.

What are the main barriers to wider vaccine use in developing countries?

Cold-chain gaps and limited veterinary infrastructure cause over 50% vaccine wastage in low-income settings, restricting effective coverage.

Why are small ruminants seen as a high-growth segment?

Sheep and goats now receive greater policy focus because Brucella melitensis is a serious human pathogen, and vaccination delivers strong economic returns for smallholders.

Page last updated on: July 1, 2025

Brucellosis Vaccines Market Report Snapshots